Objectif The group succeeded in modification of the device surfaces (including the inner surface of tubes) in order to obtain hydrophilic surfaces, and thereby to decrease the bacterial adhesion, at least in vitro. This was documented to be true for most types of plastics which are used for Medical Devices today. However, no statistical significant effect could be demonstrated in an in vivo model including plasma modified and unmodified samples of PE.As the bacterial adhesion differs very much depending on the kind of plastic material, the effect of plasma modification needs to be investigated in vivo of each relevant material, before any generalisation can take place.The plasma modification process did not alter the biocompatibility of the PE-samples in the above in vivo experiment. This also needs to be examined in each cases. By use of plasma processes the team succeeded in improving the permeability and create a barrier to relevant test gasses in order to be able to use alternative materials to soft PVC in production of medical bags. We managed to develop compounds with kinking and mechanical properties better than the commercial PVC-alternatives tested, but not as good as PVC. The possibilities of using plasma processes as a simultaneous sterilization method were documented to be very promising. It was demonstrated that active species in different plasmas were able to destroy test bacteria.The increasing application of medical devices has caused a dramatic increase in the number of device-related infections. At the same time the part of the European Medical Device Industry dealing with plastics is faced by environmental demands for finding alternatives to PVC as well as toxicological demands for finding an alternative to the ethylene-oxide sterilization method.The objectives of this research are therefore by strategic efforts to solve these problems including technical development within plasmapolymerization techniques.The research will include the development and optimization of medical plastics by compounding techniques as well as development and improvement of biological tests for evaluation of the ability of the developed materials to resist infections. Champ scientifique natural sciencesbiological sciencesmicrobiologybacteriology Programme(s) FP3-BRITE/EURAM 2 - Specific programme (EEC) of research and technological development in the field of industrial and materials technologies, 1990-1994 Thème(s) 1.4.5 - Biomaterials Appel à propositions Data not available Régime de financement CSC - Cost-sharing contracts Coordinateur Danish Technological Institute (DTI) Contribution de l’UE Aucune donnée Adresse Gregersensvej DK-2630 Taastrup Danemark Voir sur la carte Coût total Aucune donnée Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire BAXTER R&D EUROPE Belgique Contribution de l’UE Aucune donnée Adresse 7 RUE DU PROGRES 1400 NIVELLES Voir sur la carte Coût total Aucune donnée Plasma Technology Ltd Royaume-Uni Contribution de l’UE Aucune donnée Adresse North End Yatton BS19 4AP Bristol Voir sur la carte Coût total Aucune donnée STATENS SERUMINSTITUT Danemark Contribution de l’UE Aucune donnée Adresse ARTILLERIVEJ 5 2300 COPENHAGEN S Voir sur la carte Coût total Aucune donnée TOTAX PLASTIC A/S Danemark Contribution de l’UE Aucune donnée Adresse STAKTOFTEN 22 2950 VEDBAEK Voir sur la carte Coût total Aucune donnée